Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Cohn

Showing results (271-280 of 302) with videos related to

Pageof 31
Sort By:
Gynecologic Oncology|July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survivalCasey M Cosgrove, David E Cohn, Heather Hampel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian CancerAlexi A Wright, Angel Cronin, Dana E Milne, et al.
Oncology Reports|September 3, 2009
Identification of candidate epigenetic biomarkers for ovarian cancer detectionYi-Wen Huang, Rachel A Jansen, Enrica Fabbri, et al.
Gynecologic Oncology|January 4, 2021
Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patientsHeather Hampel, Rachel Pearlman, Albert de la Chapelle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2020
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)David S Miller, Virginia L Filiaci, Robert S Mannel, et al.
Gynecologic Oncology|November 25, 2019
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG studyPhuong L Mai, Helen Q Huang, Lari B Wenzel, et al.
JNCI Cancer Spectrum|April 28, 2020
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)Phuong L Mai, Austin Miller, Mitchell H Gail, et al.
Cancer Research|October 3, 2007
Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer PatientsHeather Hampel, Jenny Panescu, Janet Lockman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyD Scott McMeekin, David L Tritchler, David E Cohn, et al.
Gastroenterology|June 16, 2016
Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair GenesStacey A Cohen, Emily H Turner, Mallory B Beightol, et al.
Pageof 31

Showing results (271-280 of 302) with videos related to

Sort By:
Pageof 31
Gynecologic Oncology|July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survivalCasey M Cosgrove, David E Cohn, Heather Hampel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian CancerAlexi A Wright, Angel Cronin, Dana E Milne, et al.
Oncology Reports|September 3, 2009
Identification of candidate epigenetic biomarkers for ovarian cancer detectionYi-Wen Huang, Rachel A Jansen, Enrica Fabbri, et al.
Gynecologic Oncology|January 4, 2021
Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patientsHeather Hampel, Rachel Pearlman, Albert de la Chapelle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2020
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)David S Miller, Virginia L Filiaci, Robert S Mannel, et al.
Gynecologic Oncology|November 25, 2019
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG studyPhuong L Mai, Helen Q Huang, Lari B Wenzel, et al.
JNCI Cancer Spectrum|April 28, 2020
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)Phuong L Mai, Austin Miller, Mitchell H Gail, et al.
Cancer Research|October 3, 2007
Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer PatientsHeather Hampel, Jenny Panescu, Janet Lockman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyD Scott McMeekin, David L Tritchler, David E Cohn, et al.
Gastroenterology|June 16, 2016
Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair GenesStacey A Cohen, Emily H Turner, Mallory B Beightol, et al.
Pageof 31